Surgical Equipment & Consumables - Specialty Stocks Q3 Earnings: Intuitive Surgical (NASDAQ:ISRG) Best of the Bunch

Stock Story

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Intuitive Surgical and the best and worst performers in the surgical equipment & consumables - specialty industry.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

The 4 surgical equipment & consumables - specialty stocks we track reported a mixed Q3. As a group, revenues along with next quarter’s revenue guidance were in line with analysts’ consensus estimates.

In light of this news, share prices of the companies have held steady as they are up 1.4% on average since the latest earnings results.

Best Q3: Intuitive Surgical

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Intuitive Surgical reported revenues of $2.51 billion, up 22.9% year on year. This print exceeded analysts’ expectations by 3%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

“We’re pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and da Vinci platforms, including da Vinci 5,” said Dave Rosa, Intuitive CEO.

Intuitive Surgical pulled off the biggest analyst estimates beat and fastest revenue growth of the whole group. Unsurprisingly, the stock is up 24.3% since reporting and currently trades at $575.22.

We think Intuitive Surgical is a good business, but is it a buy today? Read our full report here, it’s free for active Edge members.

Teleflex

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $892.9 million, up 16.8% year on year, in line with analysts’ expectations. The business performed better than its peers, but it was unfortunately a mixed quarter with a beat of analysts’ EPS estimates but constant currency revenue in line with analysts’ estimates.

Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 3.4% since reporting. It currently trades at $120.52.

Is now the time to buy Teleflex? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Integra LifeSciences

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Integra LifeSciences reported revenues of $402.1 million, up 5.6% year on year, falling short of analysts’ expectations by 2.9%. It was a softer quarter as it posted revenue guidance for next quarter missing analysts’ expectations significantly and a significant miss of analysts’ revenue estimates.

Integra LifeSciences delivered the highest full-year guidance raise but had the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 14.3% since the results and currently trades at $13.23.

Read our full analysis of Integra LifeSciences’s results here.

LeMaitre

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $61.05 million, up 11.4% year on year. This number lagged analysts' expectations by 2%. Taking a step back, it was a mixed quarter as it also logged a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly.

LeMaitre had the weakest full-year guidance update among its peers. The stock is down 1.3% since reporting and currently trades at $84.53.

Read our full, actionable report on LeMaitre here, it’s free for active Edge members.

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Nyse Order Imbalance 55149.0 Shares On Sell Side

Reuters

Teleflex

-0.56%

Risk Warnings and Disclaimers

Add to Favorites

Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know

Stock Story

What Happened?

A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the ACA marketplace. An extension would likely support sustained enrollment, securing a key revenue stream for these companies.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

Surgical Equipment & Consumables - Specialty company Integra LifeSciences jumped 3%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free for active Edge members.
Healthcare Technology for Providers company Evolent Health jumped 8.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it’s free for active Edge members.
Immuno-Oncology company Incyte jumped 4%. Is now the time to buy Incyte? Access our full analysis report here, it’s free for active Edge members.
Patient Monitoring company iRhythm jumped 2.8%. Is now the time to buy iRhythm? Access our full analysis report here, it’s free for active Edge members.
Health Insurance Providers company Clover Health jumped 5.5%. Is now the time to buy Clover Health? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Evolent Health (EVH)

Evolent Health’s shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock gained 13.2% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

Evolent Health is down 61.1% since the beginning of the year, and at $4.47 per share, it is trading 66.3% below its 52-week high of $13.26 from November 2024. Investors who bought $1,000 worth of Evolent Health’s shares 5 years ago would now be looking at an investment worth $302.30.

Risk Warnings and Disclaimers

Add to Favorites

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

Stock Story

What Happened?

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

Medical Devices & Supplies - Cardiology, Neurology, Vascular company Penumbra jumped 3.7%. Is now the time to buy Penumbra? Access our full analysis report here, it’s free for active Edge members.
Branded Pharmaceuticals company Corcept jumped 3.8%. Is now the time to buy Corcept? Access our full analysis report here, it’s free for active Edge members.
Specialty Pharmaceuticals company Elanco jumped 3.6%. Is now the time to buy Elanco? Access our full analysis report here, it’s free for active Edge members.
Patient Monitoring company ResMed jumped 3.6%. Is now the time to buy ResMed? Access our full analysis report here, it’s free for active Edge members.
Surgical Equipment & Consumables - Specialty company LeMaitre jumped 4.2%. Is now the time to buy LeMaitre? Access our full analysis report here, it’s free for active Edge members.

Zooming In On LeMaitre (LMAT)

LeMaitre’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 7 months ago when the stock dropped 12.2% on the news that the company reported weak first quarter 2025 results with a significant miss on full-year EPS guidance and underwhelming EPS guidance for next quarter. On the other hand, LeMaitre's full-year revenue guidance topped analysts' expectations and organic revenue outperform Wall Street's estimates. Still, this was a weaker quarter.

LeMaitre is down 3.6% since the beginning of the year, and at $88.20 per share, it is trading 18.3% below its 52-week high of $107.97 from November 2024. Investors who bought $1,000 worth of LeMaitre’s shares 5 years ago would now be looking at an investment worth $2,268.

Risk Warnings and Disclaimers

Add to Favorites

Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know

Stock Story

What Happened?

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

Surgical Equipment & Consumables - Specialty company Teleflex jumped 5.3%. Is now the time to buy Teleflex? Access our full analysis report here, it’s free for active Edge members.
Surgical Equipment & Consumables - Diversified company Solventum jumped 4.4%. Is now the time to buy Solventum? Access our full analysis report here, it’s free for active Edge members.
Medical Devices & Supplies - Specialty company Haemonetics jumped 5.4%. Is now the time to buy Haemonetics? Access our full analysis report here, it’s free for active Edge members.
Health Insurance Providers company Centene jumped 4.4%. Is now the time to buy Centene? Access our full analysis report here, it’s free for active Edge members.
Health Insurance Providers company Molina Healthcare jumped 4.4%. Is now the time to buy Molina Healthcare? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Haemonetics (HAE)

Haemonetics’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 15 days ago when the stock gained 22.1% on the news that the company reported third-quarter results that surpassed analyst expectations and raised its full-year financial guidance.

The medical technology firm posted adjusted earnings of $1.27 per share on revenue of $327.3 million, with both figures comfortably beating Wall Street's forecasts. While total revenue declined 5.3% year-on-year, the company's organic revenue fell only 1.8%, which was significantly better than the 5.3% decline analysts had anticipated, signaling resilience in its core operations. Furthermore, Haemonetics demonstrated strong profitability and cash generation. Its operating margin expanded to 17.9% from 15% in the same quarter last year, and free cash flow was a robust $106.3 million. Bolstered by the strong performance, management lifted its full-year adjusted earnings per share guidance to a midpoint of $4.90.

Haemonetics is flat since the beginning of the year, and at $78.79 per share, it is trading 11% below its 52-week high of $88.53 from November 2024. Investors who bought $1,000 worth of Haemonetics’s shares 5 years ago would now be looking at an investment worth $669.76.

Risk Warnings and Disclaimers

Add to Favorites

Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know

Stock Story

Inspire Medical Systems

+5.25%

What Happened?

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

Dental Equipment & Technology company Align Technology jumped 6.9%. Is now the time to buy Align Technology? Access our full analysis report here, it’s free for active Edge members.
Healthcare Technology for Patients company Tandem Diabetes jumped 9.5%. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free for active Edge members.
Surgical Equipment & Consumables - Specialty company Integra LifeSciences jumped 9.8%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free for active Edge members.
Medical Devices & Supplies - Imaging, Diagnostics company Lantheus jumped 6.4%. Is now the time to buy Lantheus? Access our full analysis report here, it’s free for active Edge members.
Medical Devices & Supplies - Specialty company Inspire Medical Systems jumped 8%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Integra LifeSciences (IART)

Integra LifeSciences’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 8 days ago when the stock gained 1.7% on the news that the company received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, allowing its use in cardiac surgery.

This clearance expanded the system's approved uses to include the debridement, or removal, of unwanted soft tissue during delicate procedures such as valve replacement and repair. The approval marked a significant milestone, enabling surgeons to apply the technology in these critical operations. Mike McBreen, an executive at the company, called the clearance a “pivotal expansion” and noted that the milestone strengthened Integra's ability to offer advanced surgical solutions.

Integra LifeSciences is down 47.7% since the beginning of the year, and at $12.04 per share, it is trading 54.7% below its 52-week high of $26.55 from February 2025. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $219.70.

Risk Warnings and Disclaimers

Add to Favorites